Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway
Research payments
$28,933
Through program year 2021, $28,933 in research payments was reported against Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway, across 14 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $26,693 | 1 |
| 2020 | Research | $104 | 1 |
| 2019 | Research | $2,136 | 12 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Gail Wright Hudson, FL Named on 3 payments
- Fadi Kayali Sarasota, FL Named on 1 payment
- Neal Rothschild West Palm Beach, FL Named on 1 payment
- Johanna Bendell Nashville, TN Named on 1 payment
- John Glaspy Los Angeles, CA Named on 1 payment
- Atif Hussein Hollywood, FL Named on 1 payment
- Aung Naing Houston, TX Named on 1 payment
- William Lawler Fullerton, CA Named on 1 payment
- Ravi Patel Bakersfield, CA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.